As with other incretin-based therapies, the most commonly reported side effects include nausea, vomiting, diarrhea and constipation, particularly during dose escalation
EMERGING RISK SIGNALS A recent analysis published in The British Medical Journal (BMJ) Medicine has found that patients who discontinue GLP-1 therapies may face increased cardiovascular risks
All other authors declare that they have no conflicts of interest in the authorship or publication of this contribution
There is no specific best time to take Coenzyme Q10 / Ubidecarenone + L-Carnitine
In addition, results obtained using the experimental models of HF with preserved ejection fraction showed that semaglutide improves endothelial function and left ventricular cytoskeleton function, and restores the cardiometabolic milieu
This makes it an excellent choice for GLP-1 medication users who experience sensitive stomachs or excessive gas with other fiber supplements